1. Homepagina
  2. Aandelen
  3. BelgiŽ
  4. Euronext Bruxelles
  5. Biocartis Group NV
  6. Nieuws
  7. Persberichten
    BCART   BE0974281132

BIOCARTIS GROUP NV

(BCART)
  Rapport
Real Time Euronext Bruxelles  -  17:35 19-08-2022
1.686 EUR   -0.59%
11/08Brussel noteert vlak
AM
11/08Brusselse beurs hoger geopend
AM
27/07Melexis uitblinker op groene Brusselse beurs
AM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Communiquťs de presse de la sociťtť BIOCARTIS GROUP NV
2020PRESS RELEASE BIOCARTIS GROUP NV : Invitation to the Extraordinary Shareholders' Meeting
AQ
2020PRESS RELEASE BIOCARTIS GROUP NV : US Multicenter Study Shows Idylla™ Allows Rapid a..
AQ
2020PRESS RELEASE BIOCARTIS GROUP NV : Results of the Shareholders' Meetings held on 8 May 202..
AQ
2020PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Creates New Share Option Plan
AQ
2020PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Q1 2020 Business Update
AQ
2020PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Development of Idylla™ COVID..
AQ
2020BIOCARTIS GROUP NV : Important Notice Regarding the Annual and Extraordinary Shareholders'..
AQ
2020PRESS RELEASE BIOCARTIS GROUP NV : Important Notice Regarding the Annual and Extraordinary..
AQ
2020PRESS RELEASE BIOCARTIS GROUP NV : Invitation to the Annual and Extraordinary Shareholders..
AQ
2020PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Publication of 2019 Annual Report
AQ
2020BIOCARTIS : Announces Co-Commercialization of the SeptiCyteģ RAPID Test on Idylla™ (..
AQ
2020BIOCARTIS : Announces New Immuno-Oncology Project with Bristol-Myers Squibb Aimed at Regis..
AQ
2020PRESS RELEASE BIOCARTIS GROUP NV : Biocartis announces 2019 results and 2020 outlook
AQ
2020PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Creates New Share Option Plan & Cancels Outst..
AQ
2020PRESS RELEASE BIOCARTIS GROUP NV : Biocartis to Host Webcast for Announcement 2019 Financ..
AQ
2020PRESS RELEASE BIOCARTIS GROUP : Biocartis announces resignation cfo
AQ
2020PRESS RELEASE BIOCARTIS GROUP : Biocartis Enters into Master Collaboration Agreement with ..
AQ
2020BIOCARTIS : Meets 2019 Key Business Objectives
AQ
2020PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Meets 2019 Key Business Objectives
AQ
2019PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces 2020 Financial Calendar
AQ
2019PRESS RELEASE BIOCARTIS NV : Disclosure of a transparency notification
AQ
2019PRESS NEWS BIOCARTIS GROUP NV : Disclosure of a transparency notification
AQ
2019BIOCARTIS GROUP NV : Disclosure of transparency notifications
GL
2019BIOCARTIS GROUP NV : Disclosure of a transparency notification
GL
2019BIOCARTIS GROUP NV : Idylla(TM) MSI Performance Study Selected for Publication at ASCO Con..
GL
2019BIOCARTIS GROUP NV : Results of the annual shareholders' meeting held on 10 May 2019
GL
2019BIOCARTIS GROUP NV : Biocartis announces final terms of its eur 150 million senior unsecur..
GL
2019BIOCARTIS GROUP NV : Biocartis announces successful placement of eur 150 million senior un..
GL
2019BIOCARTIS GROUP NV : Biocartis launches convertible bonds offering of eur 125 million
GL
2019BIOCARTIS GROUP NV : Biocartis q1 2019 business update
GL
2019BIOCARTIS GROUP NV : Invitation to Annual Shareholders' Meeting
GL
2019BIOCARTIS GROUP NV : Disclosure of outstanding voting securities
GL
2019BIOCARTIS GROUP NV : Biocartis announces publication of its 2018 annual report
GL
2019BIOCARTIS GROUP NV : Biocartis and Bristol-Myers Squibb Sign Collaboration Agreement for M..
GL
2019BIOCARTIS GROUP NV : Biocartis announces CE-IVD marking of its Idylla(TM) MSI Test
GL
2019BIOCARTIS GROUP NV : Biocartis announces 2018 results and 2019 outlook
GL
2019BIOCARTIS GROUP NV : Biocartis Places Its 1,000th Idylla(TM) Instrument with Geisinger in ..
GL
2019BIOCARTIS GROUP NV : Disclosure of a transparency notification
GL
2019BIOCARTIS GROUP NV : Disclosure of a transparency notification
GL
2019BIOCARTIS GROUP NV : Biocartis successfully raises eur 55.50 million
GL
2019BIOCARTIS GROUP NV : Biocartis upsizes its equity placement due to significant demand
GL
2019BIOCARTIS GROUP NV : Biocartis launches equity placement
GL
2019BIOCARTIS : Announces Achieving its 2018 Key Business Objectives
PU
2019BIOCARTIS : and Nichirei Bioscience Announce Commercialization Collaboration for Japanese ..
PU
2019BIOCARTIS : Corporate Presentation
PU
2019BIOCARTIS GROUP NV : Biocartis Announces Achieving its 2018 Key Business Objectives
GL
2019BIOCARTIS GROUP NV : Biocartis and Nichirei Bioscience Announce Commercialization Collabor..
GL
2018BIOCARTIS : Disclosure of Outstanding Voting Securities
PU
2018BIOCARTIS GROUP NV : Disclosure of outstanding voting securities
GL
2018BIOCARTIS : Genomic Health and Biocartis Expand Collaboration to Urology with the Developm..
PU
2018BIOCARTIS : Corporate Presentation
PU
2018BIOCARTIS GROUP NV : Genomic Health and Biocartis Expand Collaboration to Urology with the..
GL
2018BIOCARTIS : and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Res..
PU
2018BIOCARTIS GROUP NV : Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung C..
GL
2018BIOCARTIS : Q3 2018 Business Update
PU
2018BIOCARTIS : Corporate Presentation
PU
2018BIOCARTIS : Eight Idylla™ Performance Studies to be Presented at the Association for..
PU
2018BIOCARTIS : Shareholding Disclosure
PU
2018BIOCARTIS : Disclosure of a transparency notification
PU
2018BIOCARTIS : Corporate Presentation
PU
2018BIOCARTIS GROUP NV : Shareholding Disclosure
GL
2018BIOCARTIS GROUP NV : Disclosure of a transparency notification
GL
2018BIOCARTIS : Studies on Idylla™ MSI and RAS liquid biopsy tests to be presented at ES..
PU
2018BIOCARTIS GROUP NV : Studies on Idylla(TM) MSI and RAS liquid biopsy tests to be presente..
GL
2018BIOCARTIS : Disclosure of Outstanding Voting Securities
PU
2018BIOCARTIS GROUP NV : Disclosure of outstanding voting securities
GL
2018BIOCARTIS : Disclosure of a transparency notification
PU
2018BIOCARTIS GROUP NV : Disclosure of a transparency notification
GL
2018BIOCARTIS : Creates New Warrant Plan
PU
2018BIOCARTIS : Special report statutory auditor pursuant to Art. 596 and 598 BCC
PU
2018BIOCARTIS GROUP NV : Biocartis Creates New Warrant Plan
GL
2018BIOCARTIS GROUP NV : Biocartis announces h1 2018 results
GL
2018BIOCARTIS : and Wondfo Announce Joint Venture for Commercialization of Idylla™ Platf..
PU
2018BIOCARTIS GROUP NV : Biocartis and Wondfo Announce Joint Venture for Commercialization of ..
GL
2018BIOCARTIS : Announces 2018 Half-Year Results on 6 September 2018
PU
Vorig1  2   3  4  5  6Volgende
Volgende evenement op BIOCARTIS GROUP NV